Abstract WP260: Pravastatin Improves Short-term Survival Rate Following Cardiac Arrest and Cardiopulumonary Resuscitation In Mice

Stroke ◽  
2013 ◽  
Vol 44 (suppl_1) ◽  
Author(s):  
Shin Nakayama ◽  
Noriko Taguchi ◽  
Makoto Tanaka
Keyword(s):  
Body Weight ◽  
Cardiac Arrest ◽  
Survival Rate ◽  
Neuronal Damage ◽  
Pleiotropic Effects ◽  
Histological Evaluation ◽  
Vehicle Group ◽  
Short Term ◽  
Term Survival ◽  
Short Term Survival

Statins (HMG-CoA reductase inhibitors) exert numerous pleiotropic effects and have been shown to attenuate ischemic injury in different rodent models of cerebral focal ischemia. Few studies have examined the effect of statins on post cardiac arrest syndrome. This study conducted cardiac arrest and cardiopulmonary resuscitation (CA/CPR) in mice and tested the hypothesis that intravenous statin after CPR improves survival rate and neurological outcomes. Methods: Adult male mice (20-26 g) were subjected to CA induced by intravenous (IV) KCL. After 8 min of CA, CPR was initiated with IV epinephrine, ventilation with 100% oxygen and chest compressions (rate 300/min). At 1 hr after return of spontaneous circulation, mice were treated with either IV injection of pravastatin (3mg/kg) or vehicle. Four days after CA/CPR, neurobehavioral assessments were performed and brains were removed for histological evaluation in hippocampus and caudateputamen. Results: No difference was found between two groups in body weight, duration of CPR and dose of epinephrine. Survival rate at 4 days after CPR was significantly higher in pravastatin group compared with vehicle group (66.7%; n=24 vs 48.4%; n=33). Neurobehavioral scores in pravastatin group were better than vehicle group at 2 to 4 days after CPR. Body weight loss in vehicle group at 4 days after CPR was higher than pravastatin group (-19.4±1.8% vs -13.4±2.0%), which indicates loss of feeding activity. Histological damages in hippocampus and caudateputamen were not statistically different between two groups (pravastatin: 23.8±7.0% vs vehicle: 35.2±9.2% in hippocampus) (pravastatin: 49.4±7.2% vs vehicle: 60.5±7.8% in caudateputamen). All values are presented as mean±SEM. Conclusions: Single IV injection of pravastatin after CA improved short-term survival and neurobehavioral score in the mouse experimental CA model. Neuronal damage in the brain region was comparable to vehicle group. These data suggest that pravastatin given after CA would be beneficial in the post resuscitation phase via systemic pleiotropic effects such as anti inflammatory response and improved vascular reactivity.

The effect of chest compression depth on short term survival during out of hospital cardiac arrest

Resuscitation ◽  
2010 ◽  
Vol 81 (2) ◽  
pp. S11
Author(s):  
Lukas R.-P. ◽  
Harding U. ◽  
Weber T.P. ◽  
Quan W. ◽  
Van Aken H. ◽  
...  
Keyword(s):  
Cardiac Arrest ◽  
Chest Compression ◽  
Short Term ◽  
Term Survival ◽  
Compression Depth ◽  
Hospital Cardiac Arrest ◽  
Short Term Survival

scholarly journals Short-Term Survival and Safety of Apatinib Combined With Oxaliplatin and S-1 in the Conversion Therapy of Unresectable Gastric Cancer

2021 ◽  
Author(s):  
Zaisheng Ye ◽  
Yi Zeng ◽  
Shenghong Wei ◽  
Yi Wang ◽  
Zhitao Lin ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Survival Rate ◽  
Objective Response ◽  
Radical Resection ◽  
R0 Resection ◽  
Conversion Therapy ◽  
Short Term ◽  
Term Survival ◽  
Unresectable Gastric Cancer ◽  
Short Term Survival

Abstract BackgroundTo investigate the short-term efficacy and safety of apatinib combined with oxaliplatin and S-1 in the treatment of unresectable gastric cancer.Patients and methodsPreviously untreated patients with unresectable HER-2-negative advanced gastric cancer were selected. All the patients received six cycles of S-1 and oxaliplatin and five cycles of apatinib, which were administered at intervals of three weeks. The surgery was performed after six cycles of drug treatment. The primary endpoints were radical resection (R0) rate and safety. This study was registered with the China Trial Register, number ChiCTR-ONC-17010430(01/12/2016-01/12/2022).ResultsA total of 39 patients were enrolled. Efficacy evaluation was feasible for 37 patients. One patient achieved complete response (CR, 2.7%), 26 patients achieved partial response (PR, 70.3%), three patients had stable disease (SD, 8.1%) and seven patients had progressive disease (PD, 18.9%). The objective response rate (ORR) was 73.0% and the disease control rate (DCR) was 81.1%. 22 patients underwent surgery, among which 14 patients underwent radical resection (R0), with a R0 resection rate of 63.6%. The 1-year survival rate of the surgical group (22 patients) was 71.1% and the 2-year survival rate was 41.1%. The median survival time was 21 months. The incidence of adverse reactions (AEs) was 100%. Leucopenia (65.3%) and granulocytopenia (69.2%) were the most common hematological AEs. The most common non-hematological AEs were fatigue (51.3%) and oral mucositis (35.9%).ConclusionApatinib combined with oxaliplatin and S-1 showed good short-term survival and acceptable safety in the conversion therapy of unresectable gastric cancer.

scholarly journals Effect of initial lactate level on short-term survival in patients with out-of-hospital cardiac arrest

2017 ◽  
Vol 17 (4) ◽  
pp. 123-127 ◽  
Author(s):  
Tuba Sarıaydın ◽  
Şeref Kerem Çorbacıoğlu ◽  
Yunsur Çevik ◽  
Emine Emektar
Keyword(s):  
Cardiac Arrest ◽  
Lactate Level ◽  
Short Term ◽  
Term Survival ◽  
Hospital Cardiac Arrest ◽  
Short Term Survival

scholarly journals Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Zaisheng Ye ◽  
Yi Zeng ◽  
Shenghong Wei ◽  
Yi Wang ◽  
Zhitao Lin ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Survival Rate ◽  
Objective Response ◽  
Radical Resection ◽  
R0 Resection ◽  
Conversion Therapy ◽  
Short Term ◽  
Term Survival ◽  
Unresectable Gastric Cancer ◽  
Short Term Survival

Abstract Background We conducted a single-arm phase II trial to investigate the short-term efficacy and safety of apatinib combined with oxaliplatin and S-1 in the treatment of unresectable gastric cancer. Patients and methods Previously untreated patients with unresectable HER-2-negative advanced gastric cancer were selected. All the patients received six cycles of S-1 and oxaliplatin and five cycles of apatinib, which were administered at intervals of three weeks. The surgery was performed after six cycles of drug treatment. The primary endpoints were radical resection (R0) rate and safety. This study was registered with the China Trial Register, number ChiCTR-ONC-17010430 (01/12/2016–01/12/2022). Results A total of 39 patients were enrolled. Efficacy evaluation was feasible for 37 patients. One patient achieved complete response (CR, 2.7%), 26 patients achieved partial response (PR, 70.3%), three patients had stable disease (SD, 8.1%) and seven patients had progressive disease (PD, 18.9%). The objective response rate (ORR) was 73.0% and the disease control rate (DCR) was 81.1%. 22 patients underwent surgery, among which 14 patients underwent radical resection (R0), with a R0 resection rate of 63.6%. The 1-year survival rate of the surgical group (22 patients) was 71.1% and the 2-year survival rate was 41.1%. The median survival time was 21 months. The incidence of adverse events (AEs) was 100%. Leucopenia (65.3%) and granulocytopenia (69.2%) were the most common hematological AEs. The most common non-hematological AEs were fatigue (51.3%) and oral mucositis (35.9%). Conclusion Apatinib combined with oxaliplatin and S-1 showed good short-term survival and acceptable safety in the conversion therapy of unresectable gastric cancer.

Sign in / Sign up

Export Citation Format

Share Document